Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

KILITCH DRUGS Gains 6%; BSE HEALTHCARE Index Up 1.0%
Tue, 10 Sep 12:2

KILITCH DRUGS Gains 6%; BSE HEALTHCARE Index Up 1.0%Image source: Sefa Ozel/www.istockphoto.com

KILITCH DRUGS share price has zoomed 6% and is presently trading at Rs 362.0.

Meanwhile, the BSE HEALTHCARE index is at 43,775.5 (up 1.0%).

Among the top gainers in the BSE HEALTHCARE index today are FDC (up 6.1%) and LAURUS LABS (up 3.8%).

NARAYANA HRUDAYALAYA (down 1.8%) and ERIS LIFESCIENCES (down 1.7%) are among the top losers today.

Over the last one year, KILITCH DRUGS has moved up from Rs 201.2 to Rs 362.0, registering a gain of Rs 160.8 (up 79.9%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,357.7 to 43,775.5, registering a gain of 54.4% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 135.8%), Jubilant Pharmova (up 126.1%) and GRANULES INDIA (up 119.6%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,815.6 (up 0.3%).

The top gainers among the BSE Sensex today are Infosys (up 1.5%) and Bharti Airtel (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 25,024.6 (up 0.4%). Divis Laboratories and LTIMINDTREE are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,880.5 to 81,815.6, registering a gain of 15,935.0 points (up 24.2%).

KILITCH DRUGS Financial Update...

KILITCH DRUGS net profit fell 96.3% YoY to Rs 1 million for the quarter ended June 2024, compared to a profit of Rs 31 million a year ago. Net sales declined 8.5% to Rs 335 million during the period as against Rs 366 million in April-June 2023.

For the year ended March 2023, KILITCH DRUGS reported 33.3% increase in net profit to Rs 83 million compared to net profit of Rs 62 million during FY22. Revenue of the company grew 22.2% to Rs 1,396 million during FY23.

The current Price to earnings ratio of KILITCH DRUGS, based on rolling 12 month earnings, stands at 54.8.


Equitymaster requests your view! Post a comment on "KILITCH DRUGS Gains 6%; BSE HEALTHCARE Index Up 1.0%". Click here!